FGF21 has been highlighted as a new drug candidate for enhancing insulin sensitivity, inducing lipolysis, and preventing diet-induced obesity in many in vitro and in vivo studies (56, –58). The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.